09.16.25 -- Lilly's Exploring A Universal AAV Purification Method

For innovative treatments like CAR-T and stem cell transplants, optimal starting material is key. Understanding collection challenges and new solutions helps ensure the best foundation for these therapies.

Which production model is best suited for your cell and gene therapies, Point-of-Care (PoC) or Decentralized Manufacturing? Explore the impact of both approaches.

Explore how the dynamic microenvironment of bioreactors influences the production of extracellular vesicles (EVs), including exosomes, secreted by human mesenchymal stromal cells (hMSCs).

Current cell harvest techniques in allogeneic manufacturing face limitations, including scalability issues and cell damage. Learn why a shift in approach is vital for high-quality, efficient production at scale.

Uncover how analytical tools assess the impact of production process choices and tissue sources on the quality of cell-derived extracellular vesicles (EVs).

Discover how transitioning from manual vial filling to single-use bag systems can reduce contamination risk, improve accuracy, and enhance GMP compliance in biopharmaceutical manufacturing.

Service expectations for life science customers have evolved. Discover a service solution that offers a comprehensive partnership, which provides proactive maintenance, expert guidance, and continuous support.

Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.

Explore four common applications of cryopreservation and the science behind selecting the appropriate materials to build single-use solutions that enable cryogenic storage for cell and gene applications.

Discover the ability of a novel HEK293 suspension cell line for efficient and scalable rAAV production across various serotypes with low encapsidated host cell DNA levels.

Find out how automating cell therapy manufacturing with a flexible platform can improve biological performance, streamline tech transfer, and support regulatory confidence for scalable, multi-site production.